[1]Lijnen PJ, Petrov VV, Fagard RH.Induction of cardiac fibrosis by transforming growth factor-beta(1).Mol Genet Metab. 2000; 71(1-2):418-435.
[2]Rosenkranz S.TGF-beta1 and angiotensin networking in cardiac remodeling.Cardiovasc Res. 2004;63(3):423-432.
[3]Rahimi RA, Leof EB.TGF-beta signaling: a tale of two responses.J Cell Biochem. 2007;102(3):593-608.
[4]Verrecchia F, Mauviel A.Transforming growth factor-beta and fibrosis.World J Gastroenterol. 2007;13(22):3056-3062.
[5]Dean RG, Balding LC, Candido R,et al.Connective tissue growth factor and cardiac fibrosis after myocardial infarction.J Histochem Cytochem. 2005;53(10):1245-1256.
[6]Lee AA, Dillmann WH, McCulloch AD,et al.Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts.J Mol Cell Cardiol. 1995;27(10):2347-2357.
[7]Evans RA, Tian YC, Steadman R,et al.TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins.Exp Cell Res. 2003;282(2):90-100.
[8]Hao J, Wang B, Jones SC, et al.Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro.Am J Physiol Heart Circ Physiol. 2000;279(6):H3020-H 3030.
[9]Gramley F, Lorenzen J, Koellensperger E, et al. Atrial fibrosis and atrial fibrillation: the role of the TGF-b1 signaling pathway. Int J Cardiol.2010;143(3):405-413.
[10]Kim SK, Pak HN, Park JH, et al. Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace. 2009;11(12):1632-1638.
[11]Clancy RM, Backer CB, Yin X, et al. Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-alpha and TGF-β1 to the pathogenesis of autoimmune-associated congenital heart block.J Immunol. 2003;171(6):3253-3261.
[12]Kapur NK, Wilson S, Yunis AA, et al. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation.2012;125(22): 2728-2738.
[13]Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27(5): 512-518.
[14]He X, Gao X, Peng L, et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ Res. 2011;108(2):164-175.
[15]Dixon IM.The soluble interleukin 6 receptor takes its place in the pantheon of interleukin 6 signaling proteins: phenoconversion of cardiac fibroblasts to myofibroblasts. Hypertension. 2010;56(2):193-195.
[16]Liu YH, D'Ambrosio M, Liao T, et al. N-acetyl-seryl-aspartyl- lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth- regulatory lectin.Am J Physiol Heart Circ Physiol. 2009; 296(2):H404-H412.
[17]de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression.Eur J Heart Fail. 2009;11(9):811-817.
[18]Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012; 58(1):267-273.
[19]Shinagawa K, Shi YF, Tardif JC, et al. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation. 2002;105(22): 2672-2678.
[20]Okuyama Y, Miyauchi Y, Park AM, et al.High resolution mapping of the pulmonary vein and the vein of Marshall during induced atrial fibrillation and atrial tachycardia in a canine model of pacing-induced congestive heart failure. J Am Coll Cardiol. 2003; 42(2):348-360.
[21]Yu L, Ruifrok WP, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107-117.
[22]Goudis CA, Kallergis EM, Vardas PE. Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace. 2012;14(5): 623-630.
[23]Narducci ML, Pelargonio G, Dello Russo A, et al. Role of tissue C-reactive protein in atrial cardiomyocytes of patients undergoing catheter ablation of atrial fibrillation: pathogenetic implications. Europace. 2011; 13(8):1133-1140.
[24]Galea R, Cardillo MT, Caroli A, et al. Inflammation and C-reactive protein in atrial fibrillation: cause or effect? Tex Heart Inst J. 2014; 41(5):461-468.
[25]Ramlawi B, Otu H, Mieno S, et al. Oxidative stress and atrial fibrillation after cardiac surgery: a case-control study. Ann Thorac Surg. 2007;84(4): 1166-1173.
[26]Kim YM, Kattach H, Ratnatunga C, et al.Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008; 51(1):68-74.
[27]Rudolph V, Andrié RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nature Med.2010;16(4): 470-474.
[28]Phillipson M, Heit B, Colarusso P, et al. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J Exp Med. 2006; 203(12):2569-2575.
[29]Ross GD.Role of the lectin domain of Mac-1/CR3 (CD11b/CD18) in regulating intercellular adhesion.Immunol Res. 2002;25(3):219-227.
[30]Xia Y, Borland G, Huang J, et al.Function of the lectin domain of Mac-1/complement receptor type 3 (CD11b/CD18) in regulating neutrophil adhesion.J Immunol. 2002; 169(11):6417-6426.
[31]Jakus Z, Berton G, Ligeti E, et al. Responses of neutrophils to anti-integrin antibodies depends on costimulation through low affinity Fc gamma Rs: full activation requires both integrin and nonintegrin signals. J Immunol. 2004; 173(3):2068-2077.
[32]Jerke U, Rolle S, Purfürst B, et al. β2 integrin-mediated cell-cell contact transfers active myeloperoxidase from neutrophils to endothelial cells.J Biol Chem.2013;288(18): 12910-12919.
[33]Reil JC, Hohl M, Oberhofer M, et al. Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling. Cardiovasc Res. 2010;87(3): 485-493.
[34]Adam O, Lavall D, Theobald K, et al.Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation.J Am Coll Cardiol. 2010; 55(5):469-440.
[35]Zhao Z, Liu T, Li G. Relaxin-2 may offer therapeutic advantages in end-stage heart failure. Int J Cardiol. 2012; 57(3): 432-433.
[36]Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology, 2004;145(9): 4125-4133.
[37]Mookerjee I, Unemori EN, DU XJ, et al.Relaxin modulates fibroblast function, collagen production, and matrix metalloproteinase-2 expression by cardiac fibroblasts.Ann N Y Acad Sci. 2005;1041:190-193.
[38]Samuel CS, Cendrawan S, Gao XM, et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest. 2011;91(5): 675-690.
[39]Lekgabe ED, Kiriazis H, Zhao C, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension.2005;46(2): 412-418.
[40]Jintang S, Alei F, Yun Z, et al. Fucoidan increases TNF-α-induced MMP-9 secretion in monocytic cell line U937. Inflamm Res. 2010;59(4): 271-276.
[41]Zhao Z, Ng CY, Liu T, et al.Relaxin as novel strategy in the management of atrial fibrillation: potential roles and future perspectives. Int J Cardiol. 2014; 171(3):e72-73.
[42]Parikh A, Patel D, McTiernan CF, et al. Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. Circulation Res. 2013; 113(3): 313-321. |